We conducted a five-year prospective controlled study of prophylaxis of Staphylococcus aureus nasal carriage and infection among patients in a hemodialysis unit. Carriers tended to have chronic colonization with a single phage type. S. aureus infections occurred significantly more frequently in carriers than in noncarriers and, in 93 percent of the infected carriers, were caused by the same phage type as that carried in the nares. Neither intravenous vancomycin nor topical bacitracin was found to be efficacious in eradicating nasal carriage. However, oral rifampin given for five days decreased S. aureus carriage over a one-month follow-up period, but within three months colonization of the nares recurred in most carriers, often with an S. aureus of the original phage type. Carriers were then randomly assigned to receive either rifampin or no prophylaxis. Rifampin was readministered at three-month intervals if culture of the anterior nares yielded S. aureus. Infections with S. aureus occurred significantly more frequently in carriers given no prophylaxis than in those given a full course of rifampin. S. aureus resistant to rifampin was isolated from the anterior nares of four patients, but these isolates were not implicated in any infections. The incidence of infection at the dialysis access site, skin, and soft tissue of patients on hemodialysis can be decreased by interventions directed at nasal carriage of S. aureus.
The clinical features, microbiological characteristics, and outcomes of 163 episodes of bacteremia occurring at a long-term-care facility were evaluated. The rate of nosocomial bacteremia increased from 0.20 to 0.36 cases/1,000 patient-days from 1985 to 1989; there was a parallel increase in the rate of all nosocomial infections combined. Bacteremia was documented in 6.5% of all hospital-acquired infections. The majority of isolates were gram-negative, and Providencia stuartii was the most common gram-negative species. Staphylococcus aureus was the most frequent isolate; one-third of S. aureus strains were resistant to methicillin. Bacteremia was polymicrobial in 36 episodes (22%), 14 of which involved an enterococcal species. Portals of entry included the urinary tract (55%), the respiratory tract (11%), and soft tissue (9%). Overall mortality was 21.5%. Death was significantly associated with residence on the intermediate-care unit, the presence of a respiratory infection, a change in mental status, and relatively recent admission. Optimal management of bacterial infection in a long-term-care setting requires the availability of blood culture results. Initial decisions about antibiotic therapy should be made in light of the likelihood of infection with multiresistant organisms and of polymicrobial infection.
Our data support an association between intravenous catheter contamination and insertion at a femoral site.
We performed a case-control study of risk factors for the acquisition of ciprofloxacin-resistant gram-negative isolates ip a Veterans Affairs medical center. Sixty-five patients with resistant isolates and 50 control patients were identified. Prior fluoroquinolone use was significantly more frequent among patients with resistant isolates than it was among controls (58 versus 20%; P = 0.0001). The association with prior quinolone use was stronger in the long-term-care division (81 versus 32%; P = 0.0005) than it was in the acute-care division (29 versus 0%; P = 0.015). On multivariate analysis, prior receipt of a fluoroquinolone was the single most significant risk factor for isolation of a ciprofloxacin-resistant gram-negative organism (P = 0.0001).The fluoroquinolone antimicrobial agent ciprofloxacin has a broad spectrum of activity against gram-positive and gram-negative bacteria (16). High-level ciprofloxacin resistance among methicillin-resistant Staphylococcus aureus strains has been reported following the use of ciprofloxacin for eradication of staphylococcal colonization (14). Resistant isolates of Pseudomonas aeruginosa and members of the family Enterobacteriaceae can be selected in vitro (3,15) and may occur in vivo after ciprofloxacin therapy (10, 13). The epidemiology of ciprofloxacin-resistant gram-negative bacilli within a hospital has not been described previously.We found widespread resistance to ciprofloxacin among gram-negative bacilli isolated in the acute-and long-termcare divisions of a Department of Veterans Affairs medical center and demonstrated an association between the acquisition of resistant organisms and prior receipt of a fluoroquinolone. MATERIALS AND METHODSDescription of the facility. The Pittsburgh Veterans Affairs Medical Center consists of two geographically separate divisiops, a 438-bed acute-care division and a 432-bed longterm-care division. The two divisions share a common microbiology laboratory, located within the acute-care division. Ciprofloxacin was introduced in January 1988. In the third quarter of 1989 the microbiology laboratory reported an apparent increase in the frequency of ciprofloxacin resistance among gram-negative isolates. We therefore instituted a prospective study of risk factors for the acquisition of ciprofloxacin-resistant bacteria.Ciprofloxacin susceptibility. Antimicrobial susceptibility testing was performed by using the Vitek system. Susceptibilities of members of the family Enterobacteriaceae and Acinetobacter spp. were determined by using GNS-F1 and GNS-F2 cards. Testing of P. aeruginosa was performed by using the GNS-PA card. Susceptibility testing of other gram-negative bacilli was performed by a disk diffusion * Corresponding author. assay (1). The equivalent MIC breakpoints for ciprofloxacin were as follows: susceptible, less than or equal to 1 ,ug/ml; resistant, greater than or equal to 4 pug/ml. Epidemiologic study. From November 1989 through April 1990, the microbiology laboratory prospectively identified patients from whom ciprofloxacin...
Our data support an association between intravenous catheter contamination and insertion at a femoral site.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.